Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

The biotech scorecard for the second quarter: 18 stock-moving events to watch

  • Adam Feuerstein

By Adam Feuerstein March 31, 2021

Reprints
Scorecard
Ryan Pierse/Getty Images

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter:

Biogen. Aducanumab. FDA. June 7. Nothing more needs to be said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
The lesson biotech absolutely should not take from Silicon…
The lesson biotech absolutely should not take from Silicon Valley Bank’s failure
Researchers devise new strategies to overcome a key CRISPR…
Researchers devise new strategies to overcome a key CRISPR flaw
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
Drugmakers push back on a clever tactic employers use…
Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

Recommended Stories